Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea Seeks New Law To Support Orphan Drugs, Ease Supply Disruptions

This article was originally published in PharmAsia News

Executive Summary

Amid continued disruptions in medicine supplies and growing need to develop orphan drugs, South Korea’s government plans to submit a bill to parliament that will enable it to designate "innovative medicines" for the treatment of fatal or incurable diseases, help speed up the development and approval of innovative drugs, as well as ease supply disruptions.

You may also be interested in...



Korea Lays Essential Drug Plans Amid Ongoing Supply Concerns

South Korea unveils measures to stabilize supply of essential drugs – including a list of the drugs to monitor, stockpile and manage – to deal with public health crises in time and guarantee treatment opportunities for the nation.

Voronoi’s Brain-Permeable NSCLC Candidate Attracts ORIC To Major Deal

Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel